Jessica Boso
Nurse Practitioner · Great Falls, MTNPI 1295489870
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,910 of the $3,921 with a category attached, or 74.2%. It is spread thinly across 24 manufacturers, the largest accounting for just 23.4%. 2025 is the largest year on record at $2,764, more than ten times the $12 reported in 2022. Among nurse practitioner clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 128 payments — averaging $30.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- TG Therapeutics, Inc.$917
- Boston Scientific$886
- AbbVie$852
- Novartis$499
- Merz Pharmaceuticals, LLC$103
- Argenx US, Inc.$87
- plus $577 from 18 others
What the payments were for
- Speaking & faculty fees$2256%
- Travel & lodging$70018%
- Food & beverage$2,91074%
- Education$852%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| TG Therapeutics, Inc. | 15 | $917 |
| Boston Scientific | 5 | $886 |
| AbbVie | 46 | $852 |
| Novartis | 25 | $499 |
| Merz Pharmaceuticals, LLC | 2 | $103 |
| Argenx US, Inc. | 4 | $87 |
| EMD Serono, Inc. | 4 | $73 |
| Teva Pharmaceuticals USA, Inc. | 3 | $73 |
| Johnson & Johnson | 2 | $42 |
| Neurelis, Inc. | 2 | $42 |
| Acadia Pharmaceuticals Inc | 2 | $38 |
| UCB, Inc. | 2 | $37 |
| Lundbeck LLC | 2 | $37 |
| AstraZeneca | 2 | $31 |
| SK Life Science, Inc. | 2 | $30 |
| Livanova USA, Inc. | 2 | $27 |
| Sanofi | 1 | $26 |
| CSL Behring | 1 | $23 |
| Biogen | 1 | $22 |
| Medtronic | 1 | $21 |
| Eisai Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
| Aucta Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,921 in reported general payments places this provider in the 95th percentile of 357 nurse practitioner providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 72 | $606,909 |
| CopaxoneGlatiramer Acetate | 13 | $75,816 |
| AmpyraDalfampridine | 13 | $55,736 |
| NuedextaDextromethorphan Hbr/Quinidine | 28 | $41,187 |
| Aimovig AutoinjectorErenumab-Aooe | 53 | $37,651 |
| Emgality PenGalcanezumab-Gnlm | 43 | $32,731 |
| Nurtec OdtRimegepant Sulfate | 17 | $31,256 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 32 | $25,057 |
| Dihydroergotamine Mesylate | 22 | $20,025 |
| BriviactBrivaracetam | 12 | $16,213 |
| Dalfampridine ErDalfampridine | 20 | $8,911 |
| FingolimodFingolimod Hcl | 11 | $6,740 |
| Teriflunomide | 24 | $3,621 |
| Memantine Hcl | 30 | $2,000 |
| Levetiracetam | 60 | $1,900 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Copaxone | $73 | $75,81613 claims |
| UCB, Inc.Briviact | $37 | $16,21312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 357 nurse practitioner providers in Montana.
Other nurse practitioner in Great Falls
- Bowen TrystiansonGreat Falls$6K
- Amber MolnarGreat Falls$4K
- Whitney McKinleyGreat Falls$3K
- Elizabeth O'ConnorGreat Falls$3K
- Vilma HerreraGreat Falls$2K
- Carrie PowellGreat Falls$2K
- Martin CamachoGreat Falls$1K
- Gina HansenGreat Falls$1K
- Khi SoldanoGreat Falls$951
- Melanie BrownGreat Falls$833
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.